- Why the Dollar Will Likely Stay Weak for Some Time
- Wall Street 'Bonuses' Disappear—but Only in Name
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
- Vioxx Showed Risk Signs Before Being Pulled: Report
- Even Buffett's Huge Fame Can't Help the Name 'Warren'
- Wave of Debt Payments Facing US Government
- JPMorgan's Dimon Could Succeed Geithner: Report
- Suze Orman’s 'A Healthier, Wealthier You'
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Rally Could 'Have Some Legs in 2010': Market Strategist
- Investors May Skew Housing Reality
- Buffett's Wealth and Fame Hasn't Helped 'Warren' As a Name
- Are Crazy Retail Deals Good for Business?
- Expect a 'Square Root-Shaped' Recovery: Chief Investor
- Obama picks Xerox CEO Burns for education role
- iBasis agrees to sweetened offer from Royal KPN
- Experts offer tips for beating career blues
- Man pleads guilty to fraud scheme against Haitians
- Roper Industries boosts dividend by 15 percent
- SAIC receives $25 million IT Navy contract
- BJ Services posts 4Q loss
- BAE Systems receives $61 million Army contract
- Anadarko well win could spell 'next mega project'
Text Size 
SOUTH SAN FRANCISCO - Poniard Pharmaceuticals Inc. said Monday its cancer drug candidate picoplatin did not help lung cancer patients live longer, sending its shares plunging in early trading.
Poniard was running a late-stage trial of picoplatin as a secondary treatment for non-small cell lung cancer, meaning the drug was given to patients who had previously been treated for the disease and had a relapse. But patients who received picoplatin did not live significantly longer than those who received the best supportive treatment, the company said.
Results are based on data from 401 patients.
Poniard said more of the patients on best supportive care had received chemotherapy in the past, which might have affected the trial results. The company said it will discuss the results with the Food and Drug Administration.
In premarket trading, Poniard stock tumbled $5.86, or 77.3 percent, to $1.72. The shares closed at $7.58 Friday and have traded between $1.05 and $9.14 in the last year.
Print
Email
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- CNBC’s Phil LeBeau took a test drive of GM’s flagship electric car. Here’s what he thought of the Volt.
- The energy company Power Efficiency is building tools that regulate the power electric motors use.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes